Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE J SINDEL

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1760464044
CMS profile
261071
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,677.16

135 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,611.79 134
Education $65.37 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE J SINDEL

NPI 1760464044 · CMS profile ID 261071

Allopathic & Osteopathic Physicians / Allergy & Immunology

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760464044?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE J SINDEL, NPI 1760464044, CMS profile ID 261071. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760464044?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LAWRENCE J SINDEL, NPI 1760464044, CMS profile ID 261071. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760464044?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LAWRENCE J SINDEL, NPI 1760464044, CMS profile ID 261071, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–135 of 135 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1760464044?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

135 matching records · $2,677.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 135 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–135 of 135.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $18.2303/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803156415 CMS
Regeneron Healthcare Solutions, Inc. $18.6503/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809625691 CMS
Advanced Respiratory, Inc $22.1603/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853537545 CMS
Optinose US, Inc. $17.3403/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851678411 CMS
GlaxoSmithKline, LLC. $24.0303/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802439845 CMS
Chiesi USA, Inc. $20.2903/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849044037 CMS
GENZYME CORPORATION $20.1203/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843524147 CMS
Gilead Sciences, Inc. $17.7303/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848279283 CMS
AstraZeneca Pharmaceuticals LP $14.3403/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829762483 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.6203/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820256643 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.5502/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763348088 CMS
AstraZeneca Pharmaceuticals LP $11.6302/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830039359 CMS
GENZYME CORPORATION $18.7502/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843524133 CMS
Nestle HealthCare Nutrition Inc. $15.0802/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820958547 CMS
GlaxoSmithKline, LLC. $6.9102/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802844951 CMS
Optinose US, Inc. $12.9702/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851678391 CMS
Regeneron Healthcare Solutions, Inc. $25.3402/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809625689 CMS
AstraZeneca Pharmaceuticals LP $15.6602/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829960551 CMS
Gilead Sciences, Inc. $14.7202/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848279281 CMS
GlaxoSmithKline, LLC. $15.4902/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802857543 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.5402/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820256637 CMS
CSL Behring $19.2502/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820153781 CMS
Chiesi USA, Inc. $16.2702/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849062195 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.8901/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820256631 CMS
AstraZeneca Pharmaceuticals LP $15.6601/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829865109 CMS
PFIZER INC. $17.7401/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832624117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.5201/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820256625 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.9501/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763348090 CMS
AstraZeneca Pharmaceuticals LP $15.6601/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829768623 CMS
GlaxoSmithKline, LLC. $3.3301/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802884183 CMS
Gilead Sciences, Inc. $14.7201/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848279279 CMS
GlaxoSmithKline, LLC. $12.0201/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803044559 CMS
Teva Pharmaceuticals USA, Inc. $14.8301/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839713461 CMS
AstraZeneca Pharmaceuticals LP $61.4601/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829771143 CMS
GENZYME CORPORATION $22.0401/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843524125 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,733.43 102
PY2020 $1,164.71 65
PY2021 $2,677.16 135
PY2022 $2,954.65 154
PY2023 $1,604.59 82
PY2024 $887.13 48
PY2025 $1,150.82 43

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $418,736.26 56
PY2024 Principal investigator $520,879.84 45
PY2023 Principal investigator $171,130.37 32
PY2022 Recipient $1,629.47 3
PY2022 Principal investigator $116,953.05 23
PY2021 Principal investigator $13,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $10,000.00 12/23/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946834
Principal investigator 1 CSL Behring $750.00 12/22/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252667987
Principal investigator 1 GlaxoSmithKline, LLC. $3,368.00 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192170141
Principal investigator 1 ModernaTX, Inc. $1,444.00 12/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011766
Principal investigator 1 ModernaTX, Inc. $30,000.00 11/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946836
Principal investigator 1 ModernaTX, Inc. $425.00 11/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011768
Principal investigator 1 GlaxoSmithKline, LLC. $832.20 10/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192165728
Principal investigator 1 GlaxoSmithKline, LLC. $15,500.00 09/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192170146
Principal investigator 1 PFIZER INC. $3,536.25 09/11/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228757803
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 08/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192166905
Principal investigator 1 GlaxoSmithKline, LLC. $2,820.00 08/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192170151
Principal investigator 1 GlaxoSmithKline, LLC. $165.00 08/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192165721
Principal investigator 1 GlaxoSmithKline, LLC. $168.00 08/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192166917
Principal investigator 1 GlaxoSmithKline, LLC. $182.00 08/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192166928
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 08/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1192170132
Principal investigator 1 PFIZER INC. $811.25 08/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228784494
Principal investigator 1 GlaxoSmithKline, LLC. $483.00 07/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192170124
Principal investigator 1 ModernaTX, Inc. $6,240.00 07/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011750
Principal investigator 1 CSL Behring $360.00 06/25/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252667971
Principal investigator 1 CSL Behring $500.00 06/25/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252667973
Principal investigator 1 ModernaTX, Inc. $33,440.00 06/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011758
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 06/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192170136
Principal investigator 1 ModernaTX, Inc. $1,485.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011746
Principal investigator 1 ModernaTX, Inc. $11,375.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011752
Principal investigator 1 PFIZER INC. $15,042.00 06/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228777641
Principal investigator 1 ModernaTX, Inc. $79,040.00 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011772
Principal investigator 1 ModernaTX, Inc. $3,340.00 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011778
Principal investigator 1 CSL Behring $1,500.00 05/23/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252667941
Principal investigator 1 CSL Behring $2,600.00 05/23/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252667943
Principal investigator 1 CSL Behring $3,500.00 05/23/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252667945
Principal investigator 1 CSL Behring $14,500.00 05/23/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252667947
Principal investigator 1 ABBVIE INC. $700.00 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon No dispute reported 06/30/2026 1202485375
Principal investigator 1 ModernaTX, Inc. $1,045.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011760
Principal investigator 1 ModernaTX, Inc. $3,325.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011762
Principal investigator 1 ModernaTX, Inc. $4,560.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011764
Principal investigator 1 GlaxoSmithKline, LLC. $1,400.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192165724
Principal investigator 1 GlaxoSmithKline, LLC. $2,898.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192166900
Principal investigator 1 GlaxoSmithKline, LLC. $45.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192166909
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192166913
Principal investigator 1 GlaxoSmithKline, LLC. $86.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192166924
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192170119
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192170127
Principal investigator 1 GlaxoSmithKline, LLC. $1,230.20 04/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1192166920
Principal investigator 1 GlaxoSmithKline, LLC. $483.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192166895
Principal investigator 1 ModernaTX, Inc. $1,520.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011748
Principal investigator 1 ModernaTX, Inc. $2,090.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011754
Principal investigator 1 ModernaTX, Inc. $3,006.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011774
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 03/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192165716
Principal investigator 1 AstraZeneca Pharmaceuticals LP $49,159.24 02/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185551951
Principal investigator 1 ModernaTX, Inc. $4,342.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011756
Principal investigator 1 CSL Behring $1,011.88 02/11/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252668049
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,443.24 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185551949
Principal investigator 1 ModernaTX, Inc. $10,020.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011770
Principal investigator 1 ModernaTX, Inc. $7,315.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253011776
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,950.00 01/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler with e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants with Asthma (4 to 11 Years Old) No dispute reported 06/30/2026 1244046682
Principal investigator 1 AstraZeneca UK Limited $8,500.00 01/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
Multicentre,Randomised,Double blind,Parallel Group,Placebo controlled,Time to first Asthma Exacerbation Phase tree Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma Dominika No dispute reported 06/30/2026 1185551947